• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LEFLUNOMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • LEFLUNOMIDE chembl:CHEMBL960 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    SULOL
    LEFLUNOMIDE
    SU-101
    ARAVA
    HWA-486
    L04AA13
    SU101
    5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-4-ISOXAZOLECARBOXAMIDE
    HWA 486
    LEFUNOMIDE
    ARAVA®
    LEFLUNOMIDA
    ALPHA,ALPHA,ALPHA-TRIFLUORO-5-METHYL-4-ISOXAZOLECARBOXY-P-TOLUIDIDE
    5-METHYLISOXAZOLE-4-CARBOXYLIC ACID (4-TRIFLUOROMETHYL)ANILIDE
    LEFUNAMIDE
    LEFLUNOMIDUM
    ARABLOC®
    chembl:CHEMBL960
    drugbank:01097
    chemidplus:75706-12-6
    rxcui:27169
    pubchem.compound:3899

    Drug Info:

    Year of Approval 1998
    Drug Class antirheumatic agents
    FDA Approval 1998
    Drug Class small molecule
    Drug Indications Antirheumatic Agents
    (4 More Sources)

    Publications:

    Schattenkirchner, 2000, The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review., Immunopharmacology
    Herrmann et al., 2000, Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases., Immunopharmacology
    Wozel et al., 2002, [Leflunomide--a new drug for pharmacological immunomodulation]., Hautarzt
    Reitzik et al., 1975, Familial polyostotic fibrous dysplasia., Oral Surg. Oral Med. Oral Pathol.
    Li et al., 2004, Leflunomide in the treatment of rheumatoid arthritis., Clin Ther
    Fukushima et al., Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice., Reprod. Toxicol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Goldenberg, 1999, Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis., Clin Ther
    Prakash et al., 1999, Leflunomide: a review of its use in active rheumatoid arthritis., Drugs
    Fox, 1998, Mechanism of action of leflunomide in rheumatoid arthritis., J Rheumatol Suppl
    Sanders et al., 2002, Leflunomide for the treatment of rheumatoid arthritis and autoimmunity., Am. J. Med. Sci.
    Breedveld et al., 2000, Leflunomide: mode of action in the treatment of rheumatoid arthritis., Ann. Rheum. Dis.
    Pawlik A et al., 2009, The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide., Pharmacogenomics
    Bohanec Grabar P et al., 2009, Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis., Drug Metab Dispos
    Bohanec Grabar P et al., 2008, Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients., Eur J Clin Pharmacol
    Kullich et al., Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis., Clin. Exp. Rheumatol.
    Kraan et al., 2000, Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients., Arthritis Rheum.
    Dziedziejko V et al., 2011, The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide., Pharmacogenomics
  • LEFLUNOMIDE   DHODH

    Interaction Score: 30.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dihydroorotate dehydrogenase inhibitor
    Trial Name -

    PMIDs:
    10878295 10878294 12063741 1060033 15189743 17604599 11752352 10890256 10651393 9666414 12003373 11053058 19207032


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • LEFLUNOMIDE   MMP1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16762150


    Sources:
    NCI

  • LEFLUNOMIDE   CXCL8

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10902750


    Sources:
    NCI

  • LEFLUNOMIDE   ESR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21174621


    Sources:
    PharmGKB

  • LEFLUNOMIDE   SMN2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEFLUNOMIDE   SMN1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEFLUNOMIDE   RAB9A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEFLUNOMIDE   CYP1A2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19581389 18496682


    Sources:
    DTC PharmGKB

  • LEFLUNOMIDE   HTT

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEFLUNOMIDE   ATAD5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEFLUNOMIDE   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LEFLUNOMIDE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: LEFLUNOMIDE

    • Version: 01-August-2011

    Alternate Names:
    LEFLUNOMIDE Primary Drug Name

    Drug Info:
    Drug Class antirheumatic agents
    Year of Approval 1998

    Publications:

  • TdgClinicalTrial: LEFLUNOMIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antirheumatic Agents
    Drug Class small molecule
    FDA Approval 1998

    Publications:

  • NCI: LEFLUNOMIDE

    • Version: 14-September-2017

    Alternate Names:
    C1128 NCI drug code

    Drug Info:

    Publications:
    Kraan et al., 2000, Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients., Arthritis Rheum.
    Kullich et al., Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis., Clin. Exp. Rheumatol.

  • PharmGKB: leflunomide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Bohanec Grabar P et al., 2009, Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis., Drug Metab Dispos
    Bohanec Grabar P et al., 2008, Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients., Eur J Clin Pharmacol
    Pawlik A et al., 2009, The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide., Pharmacogenomics

  • DTC: LEFLUNOMIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL960 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Leflunomide

    • Version: 2020.06.01

    Alternate Names:
    D08ROP TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL960

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL960

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21